AI Imaging Advantage Activ Surgical focuses on AI, ML, and AR-enabled real-time visualization to reduce surgical complications. Sales opportunities include offering AI-driven imaging enhancements, analytics subscriptions, and integration services with existing OR imaging workflows to attract hospitals seeking precision and safety gains.

Autonomous Capabilities The company completed the world’s first autonomous robotic surgery of soft tissue and is actively developing autonomous tools. Target buyers include high-end academic medical centers and surgical robotics programs interested in expanding autonomous capabilities, interoperability with current robotic platforms, and training resources for staff.

Regulatory Milestones ActivSight received CE Mark and FDA 510(k) clearance activities are noted in history. Opportunities exist to partner on regulatory strategy support, expand market access in new regions, and position compliant imaging modules as removable add-ons for existing surgical suites.

Strategic Leadership New CEO appointed in late 2022 with a strategic focus on digital surgery and AI tools. Leverage leadership change to approach enterprise buyers with a clear roadmap, ROI case studies, and executive briefings highlighting go-to-market plans and clinical validation.

Financial Position Revenue indicates a growing but mid-sized company with significant funding (~$100M). Propose tiered commercial models, volume discounts for hospital networks, and co-development or pilot programs to de-risk adoption and accelerate sales cycles.